2011 Research Agenda
TUFTS CSDD MULTI-COMPANY PROJECT SERIES
- Benchmarking Pre-clinical through Early Clinical Drug Development
- Development Program Complexity and ROI Impact
- Protocol Amendments: Incidence, Causes and Impact
- Global Landscape for Study Monitoring
- Electronic Medical Records & Health IT Solutions: Planning, Management, and Execution
- Validating and Benchmarking Development Capacity Forecasting
- Cost Drivers in Oncology Clinical Trials
- Clinical Supplies Market Analysis
- CRA Landscape Assessment
REGULATION AND GLOBAL INNOVATION TRENDS
- Pediatric Studies Update: Preparation for PDUFA V
- Translational Medicine: Progress and Trends
- Pandemic and Bioterror Countermeasures Initiatives
- Progress in Neglected Diseases Drug Development
- Academic-Industry Partnerships: Role in Innovation
R&D PERFORMANCE AND MANAGEMENT
- Tufts CSDD New R&D Cost Estimate: Cost of Drug Development
- REMS: Implementation and Impact
- Top Industry Performers Analysis
- Supplemental Indication Development and Approval Trends
- Clinical Success Rates and Firm Size
- Tracking Global Clinical Trial Activity
- Protocol Design Trends by Phase and Therapeutic Area
- New Indication Trends for Oncology Drugs
BIOTECHNOLOGY DEVELOPMENT TRENDS
- Peptide Therapeutics Development Trends
- Antibody Development Trends for Treatment of Immunological Diseases
- Alternate Antibodies and Scaffolds: Market and Partnership Potential
PHARMACEUTICAL POLICY AND MARKETING TRENDS
- Reimbursement: Role of Therapeutic Value, Cost, Cost-Effectiveness and Disease Burden
- US-UK Comparison of Prescribing Patterns
- Oncology Drug Market Access: A US-Canada Comparison
- Comparative Effectiveness Research and Its Impact on Innovation
- Personalized Medicine: Clinical and Economic Barriers
- Disease Management Trends in Three Specific Diseases